News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

Monday, 12. May 2014

Category

Publications

Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.

Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.

Published

Wednesday, 11. September 2013

Category

Publications

Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.

Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.

Published

Wednesday, 19. June 2013

Categories

PARI Publications
Publications

Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.

Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.

Published

Tuesday, 13. November 2012

Category

Publications

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Published

Friday, 09. December 2011

Category

PARI Publications

A Novel Nebuliser for the Simultaneous Administration of siRNA and Supplemental Oxygen for RSV in Infants.

A Novel Nebuliser for the Simultaneous Administration of siRNA and Supplemental Oxygen for RSV in Infants.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team